Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 44

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 44
---
suming, and could distract our technical and management personnel from their normal responsibilities. Any claims we assert against
perceived infringers could provoke these parties to assert counterclaims or file administrative actions against us alleging that we infringe
their patents. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable,
in whole or in part, construe the patent’s claims narrowly or refuse to stop the other party from using the technology at issue
on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding or administrative
action could put one or more of our patents at risk of being invalidated or interpreted narrowly. Our competitors may assert invalidity
on various grounds, including lack of novelty, obviousness or that we were not the first applicant to file a patent application related
to our product. We may elect to enter into license agreements in order to settle patent infringement claims or to resolve disputes before
litigation, and any such license agreements may require us to pay royalties and other fees that could be significant. Furthermore, because
of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our
confidential information could be compromised by disclosure.

Our competitors, many of
which have made substantial investments in patent portfolios, trade secrets, trademarks and competing technologies, may have applied
for or obtained, or may in the future apply for or obtain, patents or trademarks that may prevent, limit or otherwise interfere with
our ability to make, use, sell and/or export our products or to use our technologies or product names. Moreover, individuals and groups
that are non-practicing entities, commonly referred to as “patent trolls,” purchase patents and other intellectual property
assets for the purpose of making claims of infringement in order to extract settlements. From time to time, we may receive threatening
letters, notices or “invitations to license,” or may be the subject of claims that our products and business operations infringe
or violate the intellectual property rights of others. The defense of these matters can be time consuming, costly to defend in litigation,
divert management’s attention and resources, damage our reputation and brand and cause us to incur significant expenses or make
substantial payments.

If we fail to execute invention assignment agreements with our employees and contractors involved in the development of intellectual property or are unable to protect the confidentiality of our trade secrets, the value of our products and our business and competitive position could